东诚药业：下属公司获得药物临床试验批准通知书

Group 1 - Dongcheng Pharmaceutical (SZ 002675, latest price: 17.56 CNY) announced on August 22 that its subsidiary LNC PHARMA PTE. LTD. received approval from the U.S. Food and Drug Administration for the clinical trial of Ac-LNC1011 injection, with Phase I trials to commence shortly [2] - For the first half of 2025, Dongcheng Pharmaceutical's revenue composition is 100.0% from the biopharmaceutical industry [2]